Antidepressant Drugs and the Risk of Intracranial Bleeding: Parsing an Observational Study
Related Experiment Video
Updated: Mar 14, 2026

Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
Abstract:
Observational studies have suggested that antidepressant drug use is associated with a small but increased risk of intracranial bleeding. Because of the widespread use of antidepressant drugs and the potential public health significance of this finding, the current article critically evaluates the methodology and findings of a recently published observational study. Observational studies reveal associations, but cannot establish causality. Establishing causality from observed associations requires evidence from different scientific perspectives. Claims arising from observational studies are likely to be wrong, especially for small effects, because of bias and confounding. Statistical testing does not prove the validity of an association, nor does a meta-analysis of multiple observational studies. A valid association may not be clinically meaningful if the magnitude of the effect is small or the outcome is rare. Based on a critical analysis of these observational studies, it is concluded that the risk of intracranial bleeding associated with antidepressant drugs is likely to be a false alarm. [Journal of Psychosocial Nursing and Mental Health Services, 54(2), 21-24.].
More Related Videos
08:18Intracranial Pressure Monitoring In Nontraumatic Intraventricular Hemorrhage Rodent Model
Published on: February 8, 2022
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Drug Therapy
Antianxiety Medications
Drug Toxicity: Risk factors
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...